Abstract
Immunotherapy has emerged as a potent tool in the treatment of lung cancer, particularly in patients with advanced disease. Multiple drugs are now available which cause an anti-tumor immune response by blocking the interaction between programmed cell death protein 1 (PD-1) and its ligand, PDL1, which is expressed in some tumors. This review explores the role of immunotherapy and the practical implications of testing for PD-L1 in patients with malignant pleural effusion.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: PLEURA Journal
Paper Title
Journal
Date
